Targeting the Persister States in B-cell lymphomas
My research focuses on the specific targeting of drug-tolerant persister cancer cells in B-cell non-Hodgkin lymphomas. We aim to identify their vulnerabilities, reveal fundamental mechanisms of drug resistance and tumor persistence and accelerate biomarker and drug discovery. I define biologic dynamics within minimal residual disease (MRD) by interrogating the biophysical properties of residual lymphoma cells isolated from patients and preclinical models and relating these functional properties to drug sensitivity and underlying gene expression programs.
